EUVIMEDEUVIMED entdecken
Crossref

Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features

Yahao Wang, Zhihong Wang, Guirui Yan, Chuhang Peng, Liping Chen, Run Yan, Qinghua Wang iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Yahao Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Glucagon-Like Peptides, Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Science and Technology Major Project, National Natural Science Foundation of China, Innogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Metabolic dysfunction‐associated steatohepatitis (MASH) is a progressive liver disease with limited effective treatments. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have shown promise for metabolic and hepatic benefits. This study evaluated the therapeutic efficacy of Efsubaglutide Alfa, a novel long‐acting GLP‐1RA, in a mouse model of MASH. Materials and Methods Male C57BL/6J mice with diet‐induced obesity received a high‐fat diet and low‐dose CCl 4 injections to induce MASH. Mice were randomized to receive vehicle, obeticholic acid (OCA), semaglutide or Efsubaglutide Alfa at low, medium or high doses for 42 days. Endpoints included liver histology, collagen quantification by second harmonic generation/two‐photon excitation fluorescence (SHG/TPEF) imaging, and serum liver enzymes, lipids and metabolic parameters.

Results

By day 41, Efsubaglutide Alfa produced dose‐dependent reductions in body weight, liver weight and liver‐to‐body weight ratio versus MASH controls (all p < 0.01). Histology showed reduced steatosis and lowered the NAFLD Activity Scores (NAS), with high‐dose treatment achieving a NAS of 3.0 ± 0.47 versus 4.5 ± 0.22 in MASH controls ( p < 0.01). Although Sirius Red–based fibrosis area and scoring did not show significant differences among treatment groups, SHG/TPEF imaging analysis showed lower perisinusoidal collagen metrics (%PS: 0.27%–0.30% vs. 0.40% in MASH controls, p < 0.05). Furthermore, Efsubaglutide Alfa reduced serum ALT and AST levels and improved fasting glucose and triglycerides; fasting insulin was lower in semaglutide and high‐dose Efsubaglutide Alfa groups, consistent with improved glycaemic control.

Conclusions

Efsubaglutide Alfa reduced liver steatosis and improved SHG/TPEF‐derived perisinusoidal collagen features, which supported further evaluation of Efsubaglutide Alfa for MASH, particularly for steatosis improvement and suggests potential effects on fibrosis‐related features that warrant confirmation in longer duration studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisGlucagon-Like PeptidesNon-alcoholic Fatty Liver DiseaseFatty LiverAnimalsMaleMice, Inbred C57BLMiceLiverSemaglutideDiet, High-FatDisease Models, AnimalObesity

Stichwörter der Autor:innen

Efsubaglutide AlfaGLP‐1MASHliver biopsyliver fibrosis

Substanzen

SemaglutideGlucagon-Like Peptides

Autor:innen und Institutionen

  • Department of Endocrinology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
  • Innogen Pharmaceutical Co. Ltd., Shanghai, China.

ORCID-Profile: Qinghua Wang

Förderung

  • National Science and Technology Major Project
  • National Natural Science Foundation of China
  • Innogen

Zitieren

APA

Wang, Y., Wang, Z., Yan, G., Peng, C., Chen, L., Yan, R., & Wang, Q. (2026). Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70495

Vancouver

Wang Y, Wang Z, Yan G, Peng C, Chen L, Yan R, et al. Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70495

BibTeX
@article{Wang2026,
  author = {Wang, Yahao and Wang, Zhihong and Yan, Guirui and Peng, Chuhang and Chen, Liping and Yan, Run and Wang, Qinghua},
  title = {Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70495}
}
Kostenlos starten →